Goat Anti-Mouse IgG H&L (FITC) (ab6785)
Key features and details
- Goat Anti-Mouse IgG H&L (FITC)
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Host species: Goat
- Isotype: IgG
- Suitable for: IHC (PFA fixed), Immunomicroscopy, Flow Cyt, IHC-P, IHC-Fr, ICC/IF, ELISA, WB
Related conjugates and formulations
Overview
-
Product name
Goat Anti-Mouse IgG H&L (FITC)
See all IgG secondary antibodies -
Host species
Goat -
Target species
Mouse -
Tested applications
Suitable for: IHC (PFA fixed), Immunomicroscopy, Flow Cyt, IHC-P, IHC-Fr, ICC/IF, ELISA, WBmore details -
Immunogen
mouse whole molecule
-
Conjugation
FITC. Ex: 493nm, Em: 528nm
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 6.50
Preservative: 0.01% Sodium azide
Constituents: 0.42% Tripotassium orthophosphate, 0.87% Sodium chloride, 1% BSA -
Concentration information loading...
-
Purity
Affinity purified -
Purification notes
This product was prepared from monospecific antiserum by immunoaffinity chromatography using mouse IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. -
Conjugation notes
Diaminotriazinylaminofluorescein (DTAF) (Molecular Weight 530 daltons) Absorption Wavelength: 495 nm Emission Wavelength: 528 nm Fluorochrome/Protein Ratio: 3.3 moles FITC per mole of Goat IgG -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab6785 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC (PFA fixed) |
1/1000.
|
|
Immunomicroscopy |
Use at an assay dependent concentration.
|
|
Flow Cyt |
1/500 - 1/2500. PubMed: 17989178
|
|
IHC-P |
Use at an assay dependent concentration.
|
|
IHC-Fr |
Use at an assay dependent concentration. PubMed: 15716365For PFA fixed tissue see PMID 15716365.
|
|
ICC/IF | (1) |
1/1000 - 1/5000. (PMID16006199)
|
ELISA |
1/10000 - 1/50000.
|
|
WB |
1/10000. PubMed: 17217624
|
Notes |
---|
IHC (PFA fixed)
1/1000. |
Immunomicroscopy
Use at an assay dependent concentration. |
Flow Cyt
1/500 - 1/2500. PubMed: 17989178 |
IHC-P
Use at an assay dependent concentration. |
IHC-Fr
Use at an assay dependent concentration. PubMed: 15716365For PFA fixed tissue see PMID 15716365. |
ICC/IF
1/1000 - 1/5000. (PMID16006199) |
ELISA
1/10000 - 1/50000. |
WB
1/10000. PubMed: 17217624 |
Images
-
ab8978 staining vimentin in human colon fibroblasts by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with methanol, permeabilized with 0.1% Triton X-100 and blocked with Dako serum free protein blocker for 20 minutes at 28°C. Samples were incubated with primary antibody (1/100 in Dako antibody diluent) for 2 hours at 28°C. A FITC-conjugated goat anti-mouse IgG H&L (ab6785) (1/800) was used as the secondary antibody.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (510)
ab6785 has been referenced in 510 publications.
- Yu L et al. Extracellular vesicle-derived circCEBPZOS attenuates postmyocardial infarction remodeling by promoting angiogenesis via the miR-1178-3p/PDPK1 axis. Commun Biol 6:133 (2023). PubMed: 36726025
- Sarkis M et al. D2B-Functionalized Gold Nanoparticles: Promising Vehicles for Targeted Drug Delivery to Prostate Cancer. ACS Appl Bio Mater 6:819-827 (2023). PubMed: 36755401
- Li X et al. The members of the miR-148/152 family inhibit cancer stem cell-like properties in gastric cancer via negative regulation of ITGA5. J Transl Med 21:105 (2023). PubMed: 36765401
- Cai J et al. KDM4A, involved in the inflammatory and oxidative stress caused by traumatic brain injury-hemorrhagic shock, partly through the regulation of the microglia M1 polarization. BMC Neurosci 24:17 (2023). PubMed: 36869312
- Kaneko H et al. Zoledronate/Anti-VEGF Neutralizing Antibody Combination Administration Increases Osteal Macrophages in a Murine Model of MRONJ Stage 0-like Lesions. J Clin Med 12:N/A (2023). PubMed: 36902701